{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:20:11Z","timestamp":1760782811800},"reference-count":4,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/ndt\/gfi191","type":"journal-article","created":{"date-parts":[[2005,10,13]],"date-time":"2005-10-13T00:13:01Z","timestamp":1129162381000},"page":"549-550","source":"Crossref","is-referenced-by-count":4,"title":["\u03b1-Galactosidase activity should be examined in patients with proteinuria: what have we learned from a family affected with Fabry disease?"],"prefix":"10.1093","volume":"21","author":[{"given":"Ni-Chung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yuang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Jen","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Yung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,11]]},"reference":[{"key":"key\n\t\t\t\t20171012181950_BIB1","doi-asserted-by":"crossref","unstructured":"Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol2002; 13 [Suppl 2]: S139\u2013S143","DOI":"10.1097\/01.ASN.0000016683.73778.78"},{"key":"key\n\t\t\t\t20171012181950_BIB2","doi-asserted-by":"crossref","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet2004; 75: 65\u201374","DOI":"10.1086\/422366"},{"key":"key\n\t\t\t\t20171012181950_BIB3","doi-asserted-by":"crossref","unstructured":"del Toro N, Milan JA, Palma A. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return? Nephrol Dial Transplant2004; 19: 1018","DOI":"10.1093\/ndt\/gfh007"},{"key":"key\n\t\t\t\t20171012181950_BIB4","doi-asserted-by":"crossref","unstructured":"Nakao S, Kodama C, Takenaka T et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int2003; 64: 801\u2013807","DOI":"10.1046\/j.1523-1755.2003.00160.x"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/2\/549\/5234941\/gfi191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T23:13:12Z","timestamp":1553987592000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/2\/549\/1850667\/\u03b1Galactosidase-activity-should-be-examined-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,11]]},"references-count":4,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,10,11]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi191","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,10,11]]}}}